Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Null

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Scientific Reports|July 6, 2017
HLA-E Presents Glycopeptides from the Mycobacterium tuberculosis Protein MPT32 to Human CD8<sup>+</sup> T cellsMelanie J Harriff, Lisa M Wolfe, Gwendolyn Swarbrick, et al.
Science Immunology|July 15, 2018
MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usageMelanie J Harriff, Curtis McMurtrey, Cara A Froyd, et al.
Medrxiv : the Preprint Server for Health Sciences|December 17, 2025
Immune subphenotypes of tuberculosis and mortality in adults with sepsis and a high prevalence of HIV in East AfricaLouisa Edwards, Shevin T Jacob, Albert Majwala, et al.
PLOS Global Public Health|April 9, 2025
A narrative review of the pathophysiology of sepsis in sub-Saharan Africa: Exploring the potential for corticosteroid therapyPhoebe Gruccio, William S Girard, Amelia D Badipour, et al.
BMJ Open|June 6, 2022
Early empiric anti-<i>Mycobacterium tuberculosis</i> therapy for sepsis in sub-Saharan Africa: a protocol of a randomised clinical trialBibie Said, Edwin Nuwagira, Alphonce Liyoyo, et al.
Scientific Reports|December 29, 2022
Deaza-modification of MR1 ligands modulates recognition by MR1-restricted T cellsHaihong Jin, Nicole A Ladd, Andrew M Peev, et al.
American Journal of Respiratory and Critical Care Medicine|November 11, 2011
CD8+ T cells provide an immunologic signature of tuberculosis in young childrenChristina Lancioni, Melissa Nyendak, Sarah Kiguli, et al.
Eclinicalmedicine|March 2, 2026
Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trialEva Otoupalova, Lucas Ampaire, Megan Null, et al.
Communications Biology|February 24, 2024
Delivery of loaded MR1 monomer results in efficient ligand exchange to host MR1 and subsequent MR1T cell activationCorinna A Kulicke, Gwendolyn M Swarbrick, Nicole A Ladd, et al.
The Lancet. Infectious Diseases|January 31, 2026
Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trialScott K Heysell, Stellah G Mpagama, Edwin Nuwagira, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Scientific Reports|July 6, 2017
HLA-E Presents Glycopeptides from the Mycobacterium tuberculosis Protein MPT32 to Human CD8<sup>+</sup> T cellsMelanie J Harriff, Lisa M Wolfe, Gwendolyn Swarbrick, et al.
Science Immunology|July 15, 2018
MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usageMelanie J Harriff, Curtis McMurtrey, Cara A Froyd, et al.
Medrxiv : the Preprint Server for Health Sciences|December 17, 2025
Immune subphenotypes of tuberculosis and mortality in adults with sepsis and a high prevalence of HIV in East AfricaLouisa Edwards, Shevin T Jacob, Albert Majwala, et al.
PLOS Global Public Health|April 9, 2025
A narrative review of the pathophysiology of sepsis in sub-Saharan Africa: Exploring the potential for corticosteroid therapyPhoebe Gruccio, William S Girard, Amelia D Badipour, et al.
BMJ Open|June 6, 2022
Early empiric anti-<i>Mycobacterium tuberculosis</i> therapy for sepsis in sub-Saharan Africa: a protocol of a randomised clinical trialBibie Said, Edwin Nuwagira, Alphonce Liyoyo, et al.
Scientific Reports|December 29, 2022
Deaza-modification of MR1 ligands modulates recognition by MR1-restricted T cellsHaihong Jin, Nicole A Ladd, Andrew M Peev, et al.
American Journal of Respiratory and Critical Care Medicine|November 11, 2011
CD8+ T cells provide an immunologic signature of tuberculosis in young childrenChristina Lancioni, Melissa Nyendak, Sarah Kiguli, et al.
Eclinicalmedicine|March 2, 2026
Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trialEva Otoupalova, Lucas Ampaire, Megan Null, et al.
Communications Biology|February 24, 2024
Delivery of loaded MR1 monomer results in efficient ligand exchange to host MR1 and subsequent MR1T cell activationCorinna A Kulicke, Gwendolyn M Swarbrick, Nicole A Ladd, et al.
The Lancet. Infectious Diseases|January 31, 2026
Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trialScott K Heysell, Stellah G Mpagama, Edwin Nuwagira, et al.
Pageof 2